Eliem Therapeutics Expands Leadership Team
Eliem Therapeutics, Inc. (Nasdaq: ELYM) has announced the strategic appointments of Dr. Brett Kaplan as Chief Operating Officer and Dr. Nishi Rampal as Senior Vice President of Clinical Development. These key additions to the executive team come as the company works to enhance its management structure and drive advancements in the biotechnology sector.
Dr. Aoife Brennan, CEO of Eliem Therapeutics, shared her excitement about the new appointments: “I am thrilled to welcome Brett and Nishi to our executive team. Following the acquisition of Tenet Medicines, we have been focused on building a top-tier management team to transition Eliem into a leading biotechnology company. Brett and Nishi are vital additions to our team.”
Dr. Brennan praised Dr. Kaplan for his outstanding financial and operational leadership skills, which he has developed over his career. She also highlighted Dr. Rampal's extensive experience in clinical development strategy across various therapeutic areas, particularly those that align with Eliem’s pipeline.
Brett Kaplan’s Background
Dr. Brett Kaplan brings more than 20 years of experience in finance and operations within the biotechnology and investment banking sectors to Eliem Therapeutics. Before this new role, he served as the President, Chief Financial, and Corporate Development Officer at Chroma Medicine Inc., where he successfully raised around $250 million to advance the next generation of genomic medicines.
Previously, Dr. Kaplan held the position of Chief Financial Officer at Prevail Therapeutics, which was acquired by Eli Lilly and Company for $940 million. He also has a wealth of experience in corporate development and strategic roles at various pharmaceutical companies, including Cubist Pharmaceuticals and Biopure Corporation. Dr. Kaplan earned an MBBCh and an M.B.A. from the University of Witwatersrand.
Nishi Rampal’s Contributions
Dr. Nishi Rampal joins Eliem with over a decade of experience in the pharmaceutical and biotechnology industries, focusing on rare disease drug development. Her leadership has led to global approvals for significant treatments in neurology and rheumatology, including UPLINZA® and ULTOMIRIS.
Before her current appointment, Dr. Rampal was the Executive Director of Clinical Development at Horizon Therapeutics, where she directed the strategy for UPLINZA. Her impressive career also includes significant roles at Alexion Pharmaceuticals, where she contributed to the development of crucial treatments for myasthenia gravis. Dr. Rampal completed her neurology residency at Yale School of Medicine and her fellowship at Columbia University.
Focus on Autoimmune Diseases
Eliem Therapeutics is primarily focused on creating therapeutics for autoimmune-driven inflammatory diseases. The company’s lead asset, budoprutug, is an anti-CD19 antibody designed to treat a wide range of autoimmune conditions. This innovative treatment platform holds promise for applications in systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy.
Dr. Rampal emphasized the significant unmet medical needs in treating autoimmune diseases and expressed her commitment to advancing Eliem's mission in developing antibody-based therapies.
Looking Forward
As Eliem Therapeutics prepares for future advancements, the integration of Dr. Kaplan and Dr. Rampal into leadership roles is expected to strengthen the company's pipeline and enhance its ability to deliver transformative therapies to patients. Their expertise aligns well with Eliem’s strategic objectives in the biotechnology field.
About Eliem Therapeutics, Inc.
Eliem Therapeutics is committed to developing innovative treatments for autoimmune-driven inflammatory diseases. The company aims to advance its lead product candidate, budoprutug, targeting critical areas within the autoimmune disease spectrum. More detailed information can be found on their official website.
Contact Information
For investor inquiries, please contact:
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
339-970-2843
Frequently Asked Questions
What is the role of Brett Kaplan at Eliem Therapeutics?
Brett Kaplan has been appointed as the Chief Operating Officer, where he will oversee operational effectiveness and strategic development within the company.
What expertise does Nishi Rampal bring to her role?
Nishi Rampal has extensive experience in leading clinical development in rare disease drug development, providing strategic insights that will advance Eliem's pipeline.
What focus areas does Eliem Therapeutics target?
Eliem Therapeutics primarily focuses on developing treatments for autoimmune-driven inflammatory diseases, especially with its lead asset, budoprutug.
How has Eliem Therapeutics strengthened its management team?
With the appointments of Dr. Kaplan and Dr. Rampal, Eliem is enhancing its management team to drive strategic growth and ensure operational success.
What is the significance of budoprutug to Eliem's strategy?
Budoprutug is a potentially best-in-class anti-CD19 antibody aimed at addressing critical therapeutic needs across various autoimmune diseases.
